Inhibitor of vascular endothelial cell growth factor
AssigneeMerck & Co., Inc.
InventorsRichard L. Kendall, Kenneth A. Thomas, Jr.
Life of this patent
Estimating the term…
Abstract
The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.
Claims4
A method for inhibiting angiogenesis comprising the administration of a VEGF inhibitor protein in isolated form which comprises the amino acid sequence as set forth in SEQ ID NO:6.
A method for inhibiting angiogenesis comprising the administration of a VEGE inhibitor protein in isolated form which consists of the amino acid sequence as set forth in SEQ ID NO:6.
Dependencies are inferred from the claim text.